Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing.

Zhong Q, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey JP, Vassella E, Rogel U, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Wild PJ.

Pathol Res Pract. 2018 Jul;214(7):957-963. doi: 10.1016/j.prp.2018.05.020. Epub 2018 May 22.

PMID:
29807778
2.

Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma.

Brandt LP, Albers J, Hejhal T, Pfundstein S, Gonçalves AF, Catalano A, Wild PJ, Frew IJ.

Oncotarget. 2018 Apr 13;9(28):19753-19766. doi: 10.18632/oncotarget.24831. eCollection 2018 Apr 13.

3.

Author Correction: Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.

Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Araúzo-Bravo MJ, Santourlidis S.

Sci Rep. 2018 Apr 11;8(1):6051. doi: 10.1038/s41598-018-23158-z.

4.

Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.

Velizheva NP, Rechsteiner MP, Valtcheva N, Freiberger SN, Wong CE, Vrugt B, Zhong Q, Wagner U, Moch H, Hillinger S, Schmitt-Opitz I, Soltermann A, Wild PJ, Tischler V.

Pathol Res Pract. 2018 Apr;214(4):572-578. doi: 10.1016/j.prp.2018.02.001. Epub 2018 Feb 16.

5.

Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.

Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ.

Oncotarget. 2017 Dec 4;9(12):10284-10293. doi: 10.18632/oncotarget.22888. eCollection 2018 Feb 13.

6.

Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.

Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Araúzo-Bravo MJ, Santourlidis S.

Sci Rep. 2018 Feb 22;8(1):3477. doi: 10.1038/s41598-018-21932-7. Erratum in: Sci Rep. 2018 Apr 11;8(1):6051.

7.

Evidence of renal angiomyolipoma neoplastic stem cells arising from renal epithelial cells.

Gonçalves AF, Adlesic M, Brandt S, Hejhal T, Harlander S, Sommer L, Shakhova O, Wild PJ, Frew IJ.

Nat Commun. 2017 Nov 13;8(1):1466. doi: 10.1038/s41467-017-01514-3.

8.

[Meeting Report of the Working Group on Uropathology of the German Society of Pathology].

Wild PJ, Kristiansen G.

Pathologe. 2017 Nov;38(Suppl 2):245-246. doi: 10.1007/s00292-017-0368-8. German. No abstract available.

PMID:
29046947
9.

Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma.

Brandt LP, Albers J, Hejhal T, Catalano A, Wild PJ, Frew IJ.

PLoS One. 2017 Oct 5;12(10):e0186102. doi: 10.1371/journal.pone.0186102. eCollection 2017.

10.

Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.

Nørgaard M, Haldrup C, Storebjerg TM, Vestergaard EM, Wild PJ, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Int J Mol Sci. 2017 Sep 20;18(9). pii: E2017. doi: 10.3390/ijms18092017.

11.

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP.

Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.

12.

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.

Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W.

Nat Med. 2017 Sep;23(9):1063-1071. doi: 10.1038/nm.4378. Epub 2017 Aug 14.

13.

Prevalence and causes of abnormal PSA recovery.

Lautenbach N, Müntener M, Zanoni P, Saleh L, Saba K, Umbehr M, Velagapudi S, Hof D, Sulser T, Wild PJ, von Eckardstein A, Poyet C.

Clin Chem Lab Med. 2018 Jan 26;56(2):341-349. doi: 10.1515/cclm-2017-0246.

PMID:
28763294
14.

Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.

Harlander S, Schönenberger D, Toussaint NC, Prummer M, Catalano A, Brandt L, Moch H, Wild PJ, Frew IJ.

Nat Med. 2017 Jul;23(7):869-877. doi: 10.1038/nm.4343. Epub 2017 May 29.

15.

A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.

Zhong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp N, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild PJ.

Sci Data. 2017 Mar 14;4:170014. doi: 10.1038/sdata.2017.14.

16.

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years.

Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Rüschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J.

J Cancer. 2017 Feb 5;8(3):323-331. doi: 10.7150/jca.17482. eCollection 2017.

17.

Detecting circulating tumor DNA in renal cancer: An open challenge.

Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M.

Exp Mol Pathol. 2017 Apr;102(2):255-261. doi: 10.1016/j.yexmp.2017.02.009. Epub 2017 Feb 23.

PMID:
28214514
18.

Biobased alkylphenols from lignins via a two-step pyrolysis - Hydrodeoxygenation approach.

de Wild PJ, Huijgen WJ, Kloekhorst A, Chowdari RK, Heeres HJ.

Bioresour Technol. 2017 Apr;229:160-168. doi: 10.1016/j.biortech.2017.01.014. Epub 2017 Jan 10.

PMID:
28110233
19.

Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.

Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ.

BMC Cancer. 2017 Jan 19;17(1):66. doi: 10.1186/s12885-017-3054-6.

20.

RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Strand SH, Switnicki M, Moller M, Haldrup C, Storebjerg TM, Hedegaard J, Nordentoft I, Hoyer S, Borre M, Pedersen JS, Wild PJ, Park JY, Orntoft TF, Sorensen KD.

Oncotarget. 2017 Jan 24;8(4):5774-5788. doi: 10.18632/oncotarget.14391.

21.

[Session report of the Uropathology Working Group of the German Society of Pathology 2016].

Wild PJ, Kristiansen G.

Pathologe. 2016 Nov;37(Suppl 2):256-257. German. No abstract available.

PMID:
27638524
22.

Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.

Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rössle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V.

Cancer Cytopathol. 2017 Jan;125(1):30-40. doi: 10.1002/cncy.21771. Epub 2016 Sep 16.

23.

Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.

Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ.

Oncotarget. 2017 Feb 28;8(9):14794-14805. doi: 10.18632/oncotarget.11605.

24.

TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.

Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild PJ, Theurillat JP, Brown M.

Cancer Cell. 2016 Jun 13;29(6):846-858. doi: 10.1016/j.ccell.2016.04.012. Epub 2016 May 26.

25.

Combined deletion of Vhl, Trp53 and Kif3a causes cystic and neoplastic renal lesions.

Guinot A, Lehmann H, Wild PJ, Frew IJ.

J Pathol. 2016 Jul;239(3):365-73. doi: 10.1002/path.4736. Epub 2016 May 30.

26.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

27.

Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.

Rupp NJ, Schüffler PJ, Zhong Q, Falkner F, Rechsteiner M, Rüschoff JH, Fankhauser C, Drach M, Largo R, Tremp M, Poyet C, Sulser T, Kristiansen G, Moch H, Buhmann J, Müntener M, Wild PJ.

J Pathol Inform. 2016 Jan 29;7:3. doi: 10.4103/2153-3539.175376. eCollection 2016.

28.

Clinical impact of prostate biopsy undergrading in an academic and community setting.

Mortezavi A, Keller EX, Poyet C, Hermanns T, Saba K, Randazzo M, Fankhauser CD, Wild PJ, Moch H, Sulser T, Eberli D.

World J Urol. 2016 Oct;34(10):1481-90. doi: 10.1007/s00345-016-1788-4. Epub 2016 Mar 1.

29.

Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.

Schönenberger D, Harlander S, Rajski M, Jacobs RA, Lundby AK, Adlesic M, Hejhal T, Wild PJ, Lundby C, Frew IJ.

Cancer Res. 2016 Apr 1;76(7):2025-36. doi: 10.1158/0008-5472.CAN-15-1859. Epub 2016 Jan 12.

30.

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer.

Poyet C, Hermanns T, Zhong Q, Drescher E, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ.

Oncol Lett. 2015 Nov;10(5):2753-2760. Epub 2015 Sep 9.

31.

Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer.

Umbehr MH, Lüscher M, Hunziker R, Falkner F, Wild PJ, Poyet C, Seifert B, Müntener M.

Urol Int. 2016;96(3):309-14. doi: 10.1159/000441733. Epub 2015 Dec 16.

32.

Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.

Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C.

Oncotarget. 2015 Oct 20;6(32):32748-60. doi: 10.18632/oncotarget.4977.

33.

Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.

Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Höhn A, Rüschoff J, Zhong Q, Sulser T, Moch H, Wild PJ.

J Clin Pathol. 2015 Oct;68(10):819-24. doi: 10.1136/jclinpath-2015-202898. Epub 2015 Aug 6.

34.

Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation.

Lehmann H, Vicari D, Wild PJ, Frew IJ.

J Am Soc Nephrol. 2015 Nov;26(11):2778-88. doi: 10.1681/ASN.2014090875. Epub 2015 Mar 18.

35.

A versatile modular vector system for rapid combinatorial mammalian genetics.

Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt LP, Hejhal T, Catalano A, Busenhart P, Gonçalves AF, Brandt S, Bode PK, Bode-Lesniewska B, Wild PJ, Frew IJ.

J Clin Invest. 2015 Apr;125(4):1603-19. doi: 10.1172/JCI79743. Epub 2015 Mar 9.

36.

Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer.

Sah BR, Burger IA, Schibli R, Friebe M, Dinkelborg L, Graham K, Borkowski S, Bacher-Stier C, Valencia R, Srinivasan A, Hany TF, Mu L, Wild PJ, Schaefer NG.

J Nucl Med. 2015 Mar;56(3):372-8. doi: 10.2967/jnumed.114.147116. Epub 2015 Feb 12.

37.

In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance.

Gaisa NT, Wilms H, Wild PJ, Jakse G, Heidenreich A, Knuechel R.

Virchows Arch. 2015 Apr;466(4):423-32. doi: 10.1007/s00428-015-1726-7. Epub 2015 Feb 13.

PMID:
25677977
38.

Prognostic significance of POLE proofreading mutations in endometrial cancer.

Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL, Bosse T.

J Natl Cancer Inst. 2014 Dec 12;107(1):402. doi: 10.1093/jnci/dju402. Print 2015 Jan.

39.

Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.

Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Prive GG, Carr SA, Garraway LA.

Science. 2014 Oct 3;346(6205):85-89. doi: 10.1126/science.1250255. Epub 2014 Oct 2.

40.

Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing.

Rechsteiner M, Müller R, Reineke T, Goede J, Bohnert A, Zhong Q, Manz MG, Moch H, Wild PJ, Zimmermann DR, Tinguely M.

Exp Hematol Oncol. 2014 Jul 11;3:18. doi: 10.1186/2162-3619-3-18. eCollection 2014.

41.

KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.

Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew IJ, Wild PJ.

J Pathol. 2014 Oct;234(2):239-52. doi: 10.1002/path.4390. Epub 2014 Jul 30.

PMID:
24930886
42.

Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Clin Cancer Res. 2014 Apr 15;20(8):2169-81. doi: 10.1158/1078-0432.CCR-13-2642.

43.

Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer.

Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G.

BMC Clin Pathol. 2014 Mar 13;14(1):10. doi: 10.1186/1472-6890-14-10.

44.

Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry.

Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Schüffler PJ, Grolimund D, Buhmann JM, Brandt S, Varga Z, Wild PJ, Günther D, Bodenmiller B.

Nat Methods. 2014 Apr;11(4):417-22. doi: 10.1038/nmeth.2869. Epub 2014 Mar 2.

PMID:
24584193
45.

SPOP mutations in prostate cancer across demographically diverse patient cohorts.

Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andrén O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA.

Neoplasia. 2014 Jan;16(1):14-20.

46.

Biorefining of wheat straw using an acetic and formic acid based organosolv fractionation process.

Snelders J, Dornez E, Benjelloun-Mlayah B, Huijgen WJ, de Wild PJ, Gosselink RJ, Gerritsma J, Courtin CM.

Bioresour Technol. 2014 Mar;156:275-82. doi: 10.1016/j.biortech.2014.01.069. Epub 2014 Jan 26.

PMID:
24508905
47.

[p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumor aggressiveness in humans].

Wild PJ.

Pathologe. 2013 Nov;34 Suppl 2:180-8. doi: 10.1007/s00292-013-1859-x. German.

PMID:
24196610
48.

Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.

Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.

Virchows Arch. 2013 Nov;463(5):623-31. doi: 10.1007/s00428-013-1492-3. Epub 2013 Oct 2.

PMID:
24085553
49.

The influence of thermochemical treatments on the lignocellulosic structure of wheat straw as studied by natural abundance 13C NMR.

Habets S, de Wild PJ, Huijgen WJJ, van Eck ERH.

Bioresour Technol. 2013 Oct;146:585-590. doi: 10.1016/j.biortech.2013.07.104. Epub 2013 Jul 29.

PMID:
23973979
50.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232

Supplemental Content

Loading ...
Support Center